» Articles » PMID: 6183016

Bleomycin Clinical Pharmacology by Radioimmunoassay

Overview
Specialty Oncology
Date 1982 Jan 1
PMID 6183016
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Bleomycin pharmacokinetics were studied by radioimmunoassay in 11 patients who received 7-30 U intravenously (IV) and eight patients who received 4-30 U subcutaneously (SC). For patients who received IV bleomycin plasma disappearance was biphasic, with a mean initial half-life of 0.26 h and a terminal half-life of 2.3 h. Mean plasma drug clearance was 67.8 ml/min/m2 and the volume of distribution was 13.2 l/m2. Urinary excretion accounted for 63.9% of the drug in 24 h. After SC administration peak plasma levels occurred in 1.1 h, with a mean elimination half-life of 4.3 h. Mean plasma drug clearance was 60.5 ml/min/m2 and the volume of distribution was 19.2 l/m2. Bleomycin plasma clearance correlated well with serum creatinine (r2 = 0.72). Bleomycin has a rapid plasma elimination and urinary excretion. Bleomycin bioavailability after SC administration appears comparable to that seen after IV administration as determined by the areas under the plasma disappearance curves. Prolonged plasma levels are seen after SC injection, suggesting this route of administration can produce plasma concentrations comparable to those attained with continuous IV infusions.

Citing Articles

Bleomycin Concentration in Patients' Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group.

Groselj A, Bosnjak M, Krzan M, Kosjek T, Bottyan K, Plesnik H Pharmaceutics. 2021; 13(9).

PMID: 34575400 PMC: 8469090. DOI: 10.3390/pharmaceutics13091324.


Electrochemotherapy in head and neck cancer: A review of an emerging cancer treatment.

De Virgilio A, Ralli M, Longo L, Mancini P, Attanasio G, Atturo F Oncol Lett. 2018; 16(3):3415-3423.

PMID: 30127943 PMC: 6096208. DOI: 10.3892/ol.2018.9140.


Tumor size and effectiveness of electrochemotherapy.

Mali B, Miklavcic D, Campana L, Cemazar M, Sersa G, Snoj M Radiol Oncol. 2013; 47(1):32-41.

PMID: 23450195 PMC: 3573832. DOI: 10.2478/raon-2013-0002.


Management of cutaneous metastases using electrochemotherapy.

Matthiessen L, Chalmers R, Sainsbury D, Veeramani S, Kessell G, Humphreys A Acta Oncol. 2011; 50(5):621-9.

PMID: 21574833 PMC: 3130997. DOI: 10.3109/0284186X.2011.573626.


Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P.

Pilling D, Roife D, Wang M, Ronkainen S, Crawford J, Travis E J Immunol. 2007; 179(6):4035-44.

PMID: 17785842 PMC: 4482349. DOI: 10.4049/jimmunol.179.6.4035.


References
1.
Kramer W, Feldman S, Broughton A, Strong J, Hall S, Holoye P . The pharmacokinetics of bleomycin in man. J Clin Pharmacol. 1978; 18(7):346-52. DOI: 10.1002/j.1552-4604.1978.tb01604.x. View

2.
Crooke S, Luft F, Broughton A, Strong J, Casson K, Einhorn L . Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer. 1977; 39(4):1430-4. DOI: 10.1002/1097-0142(197704)39:4<1430::aid-cncr2820390412>3.0.co;2-v. View

3.
Crooke S, Comis R, Einhorn L, Strong J, Broughton A, Prestayko A . Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Cancer Treat Rep. 1977; 61(9):1631-6. View

4.
Onuma T, HOLLAND J, Masuda H, Waligunda J, Goldberg G . Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer. 1974; 33(5):1230-8. DOI: 10.1002/1097-0142(197405)33:5<1230::aid-cncr2820330507>3.0.co;2-c. View

5.
Strong J, Broughton A, Crooke S . Specificity of antisera produced against bleomycin. Cancer Treat Rep. 1977; 61(8):1509-12. View